enalaprilat | 84799-87-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: enalaprilat
• 英文别名: enalaprilate；N-(1-carboxy-3-phenylpropyl)-L-alanyl-L-proline；1-[2-(1-Carboxy-3-phenyl-propylamino)-propionyl]-pyrrolidine-2-carboxylic acid；(2S)-1-[(2S)-2-[(1-carboxy-3-phenylpropyl)amino]propanoyl]pyrrolidine-2-carboxylic acid
• CAS: 84799-87-1
• 化学式: C₁₈H₂₄N₂O₅
• 分子量: 348.399
• InChiKey: LZFZMUMEGBBDTC-JDLVMGNASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  enalaprilat 以 乙醇 为溶剂， 生成 N-(1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline ethyl ester
  参考文献：
  名称：

  Aminoacid derivatives as antihypertensives

  摘要：

  这项发明涉及新的羧基烷基二肽衍生物和相关化合物，可用作降压药。

  公开号：

  US04374829A1
• 作为产物：
  描述：

  alanylproline hydrochloride 在 盐酸 、 sodium hydroxide 、 sodium tetrahydroborate 、 sodium cyanoborohydride 作用下， 以 水 为溶剂， 反应 2.0h， 生成 enalaprilat
  参考文献：
  名称：

  Synthesis of N-(1-carboxy-3-phenylpropen-2yl)alanylproline

  摘要：

  DOI：

  10.1007/bf01165900

文献信息

• Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
  申请人：deLong A. Mitchell

  公开号：US20070254920A1

  公开（公告）日：2007-11-01

  This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula wherein is a biologically-active moiety comprising a carboxylic acid functional group, and R b is a homotopically-symmetrical alcohol bonded to the biologically-active moiety through the carboxylic acid functional group to form an ester linkage, as well as optical isomers, enantiomers, pharmaceutically acceptable salts, biohydrolyzable amides, esters, and imides thereof and combinations thereof.

  这项发明涉及新型同位素前药、药物以及其制备、测试和使用方法。在一个实施例中，同位素前药具有一般公式 其中 是包含羧酸官能团的生物活性基团，而 R b 是通过羧酸官能团与生物活性基团形成酯键的同位对称醇，以及其光学异构体、对映异构体、药用可接受盐、生物水解酰胺、酯、亚酰胺及其组合物。
• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF
  申请人：JENKEM TECHNOLOGY CO. LTD. TIANJIN BRANCH

  公开号：US20150359900A1

  公开（公告）日：2015-12-17

  A conjugate of water soluble polymer-amino acid oligopeptide-drug of Formula (I) below and a pharmaceutical composition comprising the conjugate are provided. In the conjugate, P is a water soluble polymer; X is a linking group, wherein the linking group links P and A 1 ; each of A 1 , A 2 and A 3 is independently same or different amino acid residue or amino acid analogue residue; each of D 1 and D 2 is independently same or different drug molecule residue; a is 0 or 1; b is an integer of 2-12; c is an integer of 0-7; d is 0 or 1. The conjugate could improve drug load capacity, water solubility, stability and activity of the drug.

  提供一种水溶性聚合物-氨基酸寡肽-药物的共轭物，其化学式（I）如下，并提供包含该共轭物的制药组合物。在该共轭物中，P是水溶性聚合物；X是一个连接基团，连接基团连接P和A1；A1、A2和A3中的每一个独立地是相同或不同的氨基酸残基或氨基酸类似物残基；D1和D2中的每一个独立地是相同或不同的药物分子残基；a为0或1；b是2-12的整数；c是0-7的整数；d为0或1。该共轭物能够提高药物的载荷能力、水溶性、稳定性和活性。
• Ophthamological drugs
  申请人：Toone J. Eric

  公开号：US20060135609A1

  公开（公告）日：2006-06-22

  The present invention relates generally to ophthamological drugs. More specifically, the inventon relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.

  本发明一般涉及眼科药物。更具体地，本发明涉及一种修改（衍生化）眼科药物的方法，以增加它们通过角膜的渗透性。本发明还涉及根据本方法修改（衍生化）的药物，以及将其用于治疗与眼内压升高相关的疾病，特别是青光眼。
• Process for preparation of carboxyalkyldipeptide derivatives
  申请人：Merck & Co., Inc.

  公开号：EP0079521A1

  公开（公告）日：1983-05-25

  A process for the preparation of carboxyalkyldipeptide compounds of the Formula is described wherein R6 is hydroxy, loweralkoxy, or amino; R, R2 and R7 are hydrogen or loweralkyl; R3 is, e.g., hydrogen, or loweralkyl, R' is, e.g., hydrogen, or alkyl of from 1 to 20 carbon atoms, R4 is hydrogen or loweralkyl, R5 is, e.g., hydrogen, or loweralkyl, and, R4 and R5 may be connected together to form an alyklene bridge of from 2 to 4 carbon atoms. The process comprises reacting a compound of the Formula with a dipeptide (or protected dipeptide) of the Formula and an alkali metal cyanide or a trimethylsilycyanide, to form an amino nitrile compound of the Formula followed by hydrolysis. These compounds are useful as converting enzyme inhibitors and as antihypertensive agents.

  描述了一种制备Formula的羧基烷基二肽化合物的过程，其中R6为羟基、低烷氧基或氨基；R、R2和R7为氢或低烷基；R3为氢、低烷基等；R'为氢、1-20碳原子的烷基等；R4为氢或低烷基；R5为氢、低烷基等，R4和R5可以连接在一起形成2-4个碳原子的烷基桥。该过程包括将Formula的化合物与Formula的二肽（或保护的二肽）和碱金属氰化物或三甲基硅氰化物反应，形成Formula的氨基腈化合物，然后进行水解。这些化合物可用作转化酶抑制剂和降压剂。